0

Comparative Evaluation of Clinical Efficacy of β-tri Calcium Phosphate (Septodont-RTR)™ Alone and in Combination With Platelet Rich Plasma for Treatment of Intrabony Defects in Chronic Periodontitis

Jyostna Pinipe, Narendra Babu Mandalapu, Sesha Reddy Manchala, Satheesh Mannem, N V S Sruthima Gottumukkala, Suneetha Koneru

J Indian Soc Periodontol. 2014 May;18(3):346-51.

PMID: 25024549

Abstract:

Aim:
To assess the clinical outcome by comparing β-tri calcium phosphate (Septodont RTR)™ along with platelet rich plasma (PRP) and β-tri calcium phosphate (β-TCP) alone in intrabony defects, by clinical evaluation in a 6-month analysis.
Methodology:
Ten patients participated in the study. Using a split-mouth design, interproximal bony defects were surgically treated with either platelet rich plasma (PRP) combined with β-tri calcium phosphate (β-TCP) or β-TCP alone. Plaque Index (PI), Gingival Index, Probing Pocket Depth (PPD), Clinical Attachment Level (CAL) were recorded 6 months after surgery.
Results:
At 6 months after therapy, the PRP combined with β-TCP group showed mean PPD reduction of 2.50, CAL mean gain of 2.60 + 1.43. The β-TCP group showed mean PPD reduction of 2.80 mm, mean CAL gain of 2.60 mm. On intra-group comparison, there was greater PPD reduction and CAL gain at 6 months in both the groups. In intergroup comparison of PRP/β-TCP and β-TCP alone, there was no statistical significant difference observed. (P = 0.55, and 0.87 for PPD and CAL gain).
Conclusion:
Both therapies resulted in significant PPD reduction, CAL gain. The present study shows that treatment of intrabony periodontal defects with combination of PRP and β-TCP does not have additional improvements when compared with β-TCP alone within 6 months follow-up.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP7758874 β-tri-Calcium phosphate β-tri-Calcium phosphate 7758-87-4 Price
qrcode